Aminoglycoside susceptibility profiles of Enterobacter cloacae isolates harboring the aac(6')-Ib gene.

Korean Journal of Laboratory Medicine Pub Date : 2011-10-01 Epub Date: 2011-10-03 DOI:10.3343/kjlm.2011.31.4.279
Soo-Young Kim, Yeon-Joon Park, Jin Kyung Yu, Yeong Sic Kim
{"title":"Aminoglycoside susceptibility profiles of Enterobacter cloacae isolates harboring the aac(6')-Ib gene.","authors":"Soo-Young Kim,&nbsp;Yeon-Joon Park,&nbsp;Jin Kyung Yu,&nbsp;Yeong Sic Kim","doi":"10.3343/kjlm.2011.31.4.279","DOIUrl":null,"url":null,"abstract":"<p><p>The aminoglycoside 6'-N-acetyltransferases of type Ib (aac(6')-Ib) gene confers resistance to amikacin, tobramycin, kanamycin, and netilmicin but not gentamicin. However, some isolates harboring this gene show reduced susceptibility to amikacin. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends a revision of the phenotypic description for isolates harboring the aac(6')-Ib gene. In this study, we determined the aminoglycoside susceptibility profiles of 58 AAC(6')-Ib-producing Enterobacter cloacae isolates. On the basis of the CLSI and EUCAST breakpoints, a large proportion (84.5% and 55.2%, respectively) of these 58 isolates were found to be susceptible to amikacin. However, among the isolates that were shown to be anikacin-susceptible according to the CLSI and EUCAST breakpoints, only 30.6% and 18.8% isolates, respectively, could be considered to have intermediate resistance on the basis of the EUCAST expert rules. Further studies should be conducted to determine the aminoglycoside susceptibility profiles of aac(6')-Ib-harboring isolates from various geographic regions and to monitor the therapeutic efficacy of amikacin in infections caused by these isolates.</p>","PeriodicalId":17890,"journal":{"name":"Korean Journal of Laboratory Medicine","volume":"31 4","pages":"279-81"},"PeriodicalIF":0.0000,"publicationDate":"2011-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3343/kjlm.2011.31.4.279","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3343/kjlm.2011.31.4.279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/10/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

The aminoglycoside 6'-N-acetyltransferases of type Ib (aac(6')-Ib) gene confers resistance to amikacin, tobramycin, kanamycin, and netilmicin but not gentamicin. However, some isolates harboring this gene show reduced susceptibility to amikacin. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends a revision of the phenotypic description for isolates harboring the aac(6')-Ib gene. In this study, we determined the aminoglycoside susceptibility profiles of 58 AAC(6')-Ib-producing Enterobacter cloacae isolates. On the basis of the CLSI and EUCAST breakpoints, a large proportion (84.5% and 55.2%, respectively) of these 58 isolates were found to be susceptible to amikacin. However, among the isolates that were shown to be anikacin-susceptible according to the CLSI and EUCAST breakpoints, only 30.6% and 18.8% isolates, respectively, could be considered to have intermediate resistance on the basis of the EUCAST expert rules. Further studies should be conducted to determine the aminoglycoside susceptibility profiles of aac(6')-Ib-harboring isolates from various geographic regions and to monitor the therapeutic efficacy of amikacin in infections caused by these isolates.

Abstract Image

Abstract Image

Abstract Image

携带aac(6’)-Ib基因的阴沟肠杆菌的氨基糖苷敏感性分析
Ib型氨基糖苷6′- n -乙酰转移酶(aac(6′)-Ib)基因对阿米卡星、妥布霉素、卡那霉素和奈替霉素产生耐药性,但对庆大霉素没有耐药性。然而,一些含有该基因的分离株对阿米卡星的易感性降低。欧洲抗微生物药敏试验委员会(EUCAST)建议对携带aac(6’)-Ib基因的分离株的表型描述进行修订。在这项研究中,我们测定了58株产生AAC(6’)- ib的阴沟肠杆菌的氨基糖苷敏感性谱。根据CLSI和EUCAST的断点,这58株菌株中有很大比例(分别为84.5%和55.2%)对阿米卡星敏感。然而,在根据CLSI和EUCAST断点显示为抗虫素敏感的分离株中,根据EUCAST专家规则,分别只有30.6%和18.8%的分离株可被认为具有中间耐药。进一步的研究应确定来自不同地理区域的aac(6’)- ib分离株的氨基糖苷敏感性谱,并监测阿米卡星对这些分离株感染的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Korean Journal of Laboratory Medicine
Korean Journal of Laboratory Medicine 医学-医学实验技术
自引率
0.00%
发文量
1
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信